s90K/Mac-2BP Human ELISA

Summary

90K/Mac-2 BP (90 kDa) is a human serum glycoprotein, originally identified in the supernatant of human breast cancer cells.Serum levels of 90K/Mac-2 BP have been determined in patients with various forms of neoplasia and with some viral infections. In breast and colorectal cancer and in non-Hodgkin lymphoma, high levels of 90K/Mac-2 BP are correlated with a poor prognosis. The determination of 90K/Mac-2 BP in the serum can be used as a valuable parameter for monitoring the outcome of cancer and viral infections.

Research topic

Immune Response, Infection and Inflammation, Oncology

Assay format

Sandwich ELISA, HRP-labelled antibody

Applications

Cell culture supernatant, Serum

Sample requirements

100 µl (1:100 prediluted)

Storage/Shipping

2–8°C

Calibration range

12.5 – 200 ng/ml

Limit of detection

0.92 ng/ml

Intra-assay

CV = 5.5%

Inter-assay

CV = 11.9%

Spiking Recovery

116%

Dilution Linearity

103.7%

References to summary

• . 90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. J Acquir Immune Defic Syndr. 1993 Apr;6 (4):370-5
• . A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. AIDS Res Hum Retroviruses. 1993 Sep;9 (9):811-6
• . A tumor-derived protein which provides T-cell costimulation through accessory cell activation. J Immunother Emphasis Tumor Im. 1995 May;17 (4):209-21
• . Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci U S A. 1993 Apr 15;90 (8):3466-70
• . Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986 Jun;46 (6):3005-10
• . Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. Br J Cancer. 1993 Mar;67 (3):564-7
• . Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996 Aug;25 (2):212-7
• . Predictive value of multiple tumor marker assays in second-look procedures for ovarian cancer. Gynecol Oncol. 1989 Dec;35 (3):286-9
• . Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer. 1994 Jan;69 (1):172-6
• . Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. Br J Haematol. 1993 Sep;85 (1):207-9
• . Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. Cancer. 1990 Mar 15;65 (6):1325-8
• . Suppression of tumor growth in vivo by local and systemic 90K level increase. Cancer Res. 1995 Aug 1;55 (15):3223-7
• . The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem. 1994 Jul 15;269 (28):18401-7
• . Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. J Infect Dis. 1991 Sep;164 (3):616-7
• Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996 Aug;25 (2):212-7
• Benedetti Panici P, Scambia G, Baiocchi G, Iacobelli S, Mancuso S. Predictive value of multiple tumor marker assays in second-look procedures for ovarian cancer. Gynecol Oncol. 1989 Dec;35 (3):286-9
• Briggs NC, Natoli C, Tinari N, D'Egidio M, Goedert JJ, Iacobelli S. A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. AIDS Res Hum Retroviruses. 1993 Sep;9 (9):811-6
• Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986 Jun;46 (6):3005-10
• Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C, Di Stefano P, Natoli C. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer. 1994 Jan;69 (1):172-6
• Jallal B, Powell J, Zachwieja J, Brakebusch C, Germain L, Jacobs J, Iacobelli S, Ullrich A. Suppression of tumor growth in vivo by local and systemic 90K level increase. Cancer Res. 1995 Aug 1;55 (15):3223-7
• Longo G, Natoli C, Rafanelli D, Tinari N, Morfini M, Rossi-Ferrini P, D'Ostilio N, Iacobelli S. Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. Br J Haematol. 1993 Sep;85 (1):207-9
• Lotz MM, Andrews CW Jr, Korzelius CA, Lee EC, Steele GD Jr, Clarke A, Mercurio AM. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci U S A. 1993 Apr 15;90 (8):3466-70
• Natoli C, Dianzani F, Mazzotta F, Balocchini E, Pierotti P, Antonelli G, Iacobelli S. 90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. J Acquir Immune Defic Syndr. 1993 Apr;6 (4):370-5
• Natoli C, Garufi C, Tinari N, D'Egidio M, Lesti G, Gaspari LA, Visini R, Iacobelli S. Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. Br J Cancer. 1993 Mar;67 (3):564-7
• Natoli C, Iacobelli S, Ghinelli F. Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. J Infect Dis. 1991 Sep;164 (3):616-7
• Powell TJ, Schreck R, McCall M, Hui T, Rice A, App H, Azam M, Ullrich A, Shawver LK. A tumor-derived protein which provides T-cell costimulation through accessory cell activation. J Immunother Emphasis Tumor Im. 1995 May;17 (4):209-21
• Scambia G, Panici PB, Iacobelli S, Baiocchi G, Battaglia F, Perrone L, Sonsini C, Ferrandina G, Natoli C, Mancuso S. Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. Cancer. 1990 Mar 15;65 (6):1325-8
• Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem. 1994 Jul 15;269 (28):18401-7

By research topic:

• Immune Response, Infection and Inflammation
• Oncology

By molecule:

• 90K/Mac-2BP